Jazz Pharmaceuticals plc

NASDAQ:JAZZ   4:00:00 PM EDT
109.29
-1.02 (-0.92%)
6:28:20 PM EDT: $110.00 +0.71 (+0.65%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)6.89B
Current PE16.61
Forward PE 5.88
2yr Forward PE 5.25
See more stats
Estimates Current Quarter
Revenue$1.01 Billion
Adjusted EPS$4.76
See more estimates
10-Day MA$109.86
50-Day MA$116.66
200-Day MA$125.06
See more pivots

Jazz Pharmaceuticals plc Stock, NASDAQ:JAZZ

Waterloo Exchange, Waterloo Road, Dublin, Dublin 4
Ireland
Phone: +353.1.634.7800
Number of Employees: 2800
http://www.jazzpharmaceuticals.com

Description

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.